1. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and alzheimer's disease. N Engl J Med. 2002. 346:476–483.
Article
2. Zoccolella S, Lamberti SV, Iliceto G, Santamato A, Lamberti P, Logroscino G. Hyperhomocysteinemia in l-dopa treated patients with parkinson's disease: potential implications in cognitive dysfunction and dementia? Curr Med Chem. 2010. 17:3253–3261.
Article
3. Ramakrishnan S, Sulochana KN, Lakshmi S, Selvi R, Angayarkanni N. Biochemistry of homocysteine in health and diseases. Indian J Biochem Biophys. 2006. 43:275–283.
Article
4. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB, et al. Homocysteine and cognitive impairment in parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord. 2009. 24:1437–1444.
Article
5. O'Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in parkinson's disease. Mov Disord. 2004. 19:1403–1408.
Article
6. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement. 2011. 7:412–417.
Article
7. Muller T. Role of homocysteine in the treatment of parkinson's disease. Expert Rev Neurother. 2008. 8:957–967.
Article
8. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, et al. Effects of levodopa and comt inhibitors on plasma homocysteine in parkinson's disease patients. Mov Disord. 2005. 20:69–72.
Article
9. Nissinen E, Nissinen H, Larjonmaa H, Vaananen A, Helkamaa T, Reenila I, et al. The comt inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm. 2005. 112:1213–1221.
Article
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992. 55:181–184.
Article
11. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with lewy bodies: third report of the dlb consortium. Neurology. 2005. 65:1863–1872.
Article
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967. 17:427–442.
Article
13. Zoccolella S, dell'Aquila C, Abruzzese G, Antonini A, Bonuccelli U, Canesi M, et al. Hyperhomocysteinemia in levodopa-treated patients with parkinson's disease dementia. Mov Disord. 2009. 24:1028–1033.
Article
14. Nevrly M, Kanovsky P, Vranova H, Langova K, Hlustik P. Effect of levodopa and entacapone treatment on plasma homocysteine levels in parkinsons disease patients. Parkinsonism Relat Disord. 2009. 15:477–478.
Article
15. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated parkinson patients. Parkinsonism Relat Disord. 2005. 11:253–256.
Article
16. Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti SV, Mastronardi R, et al. Plasma homocysteine levels in parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord. 2005. 11:131–133.
Article